Using estimate of value of drug currently, ‘$300mm’ before phase 2 is finished, double w good results. Heard $300mm figure from a retired top biotech stock analyst. Only reason it’s not there now is overhanging baggage from past issues w public company lawsuit against Laidlaw...etc. If it were a private VC project est “$300mm”
It’s a perception problem but provides brief value opportunity IF the drug works.
I’ve always used 30mm shares AIO estimate, which would be $10/ share. Not worried about dilution, cash is King at this point, improves negotiating position after phase 2?
If Phase 2 is strong....
I could be wrong on everything here but I think it’s an 80% probability now. Wish I was a fly on the Wall in Hollywood right now. Again I assume the poster gives compelling data or they wouldn’t be there.
Hope they get uplisted and attend the JPM biotech conference next month.
Big unanswered question is has CC invested in the PIPE if not why not?
News 
Market Data 
Discover 
